Charles Collins-Chase, partner, and Harry Muttock, associate, at international IP law firm, Finnegan, explore AI’s potential and how companies can use IP to protect their investments in AI technology.
Key insights:
- Companies seeking to patent AI systems or software should draft claims that clearly reflect a technological improvement on conventional technology, with written description detailing that improvement.
- AI can also improve patient monitoring using digital tracking, more accurately track disease progression using biomarkers, and improve analysis of safety and efficacy data.
- AI can predict structure-function relationships for small-molecule drugs, identify new targets, and screen candidates by conducting molecular dynamics.
Artificial intelligence is revolutionising the pharmaceutical and biotechnology industries. Its unparalleled power to make predictions based on large data sets is advancing understanding of diseases, improving diagnostic speed and accuracy, accelerating drug discovery, and improving clinical trials.